Welcome to our dedicated page for Biocardia SEC filings (Ticker: BCDA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
BioCardia, Inc. SEC filings document a clinical-stage biotechnology and medical-device business focused on cell therapies and related delivery technologies for cardiovascular and pulmonary disease. Recent Form 8-K reports cover Regulation FD disclosures and other events involving CardiAMP clinical data, FDA and PMDA regulatory interactions, the Helix transendocardial delivery catheter, and patent protection for Heart3D Fusion Imaging software.
The company’s filings also record annual operating results, research and development activity, liquidity-related financial disclosures, and Nasdaq continued-listing compliance matters. These documents frame BCDA’s public-company record around product-development programs, regulatory pathways, intellectual property, capital and listing status, risk disclosures, and corporate reporting obligations.
BioCardia, Inc. President and CEO Peter Altman reported an open-market purchase of 5,400 shares of Common Stock at a weighted average price of $0.9645 per share. Following this transaction, he directly owns 361,985 shares. The trades were executed in multiple lots between $0.92 and $1.05 per share.
BioCardia, Inc. director Simon H. Stertzer received a grant of stock options as part of his compensation. He was awarded options to acquire 8,000 shares of BioCardia common stock at an exercise price of $1.20 per share, expiring on July 6, 2036. All of these options vest and become exercisable on the one-year anniversary of the grant date, as long as he continues as a service provider through that date. Following this grant, he holds stock options covering a total of 23,573 shares directly.
BioCardia director Marvin Slosman received a stock option grant for 8,000 shares of common stock on the reported date. The option has an exercise price of $1.20 per share and expires on July 6, 2036, bringing his directly held stock options to 20,000 shares. All 8,000 option shares vest and become exercisable on the one-year anniversary of the grant, provided he continues as a service provider through that date.
BioCardia, Inc. President and CEO Peter Altman reported routine equity compensation activity. On July 2, 2026, 54,606 shares of common stock were withheld by the company at $1.24 per share to cover income tax obligations on vested RSUs, and this did not represent a market sale by Altman. Following this tax-withholding disposition, he directly held 356,585 common shares. On July 6, 2026, he received a grant of stock options for 57,688 shares of common stock at a $1.20 exercise price, expiring on July 6, 2036, with vesting in 1/48th monthly installments beginning August 6, 2026, contingent on continued service, resulting in 147,903 options held after the grant.
BioCardia, Inc. Chief Financial Officer David McClung reported routine equity compensation and related tax withholding transactions. He received a grant of 41,501 stock options, each giving the right to buy common stock at $1.20 per share. The option vests in equal monthly installments over 48 months starting on August 6, 2026, and expires on July 6, 2036.
Separately, 23,125 shares of common stock were withheld by BioCardia at $1.24 per share to cover income tax obligations from restricted stock units that vested on June 29, 2026. The footnote specifies this withholding does not represent an open-market sale by McClung. After these transactions, he holds 114,245 common shares and 87,841 stock options directly.
BioCardia, Inc. Senior Vice President, Devices Edward M. Gillis received a stock option grant and had shares withheld for taxes in a routine compensation-related filing. He was granted options for 29,442 shares of common stock at an exercise price of $1.20 per share, vesting monthly over four years starting August 6, 2026. In a separate transaction, 17,269 common shares were withheld by BioCardia at $1.24 per share to cover income tax obligations on RSUs that vested June 29, 2026, which the company states does not represent a sale by him. Following these transactions, he directly holds 61,139 stock options and 54,126 common shares.
BioCardia director Andrew Scott Blank received an option grant for 8,000 shares of common stock. The stock option has an exercise price of $1.20 per share and expires on July 6, 2036. Following this grant, Blank holds 23,313 derivative securities representing options. According to the footnote, all 8,000 option shares vest and become exercisable on the one-year anniversary of the grant date, provided he continues as a service provider through that date.
BioCardia, Inc. director Jim L. Allen received a grant of 8,000 stock options to buy common stock at an exercise price of $1.20 per share. These options vest and become exercisable in full on the one-year anniversary of the grant date, if he continues as a service provider through that date.
After this award, he holds 23,313 stock options in total. This is a compensation-related grant rather than an open-market stock purchase or sale.
BioCardia, Inc. director Jay M. Moyes received a grant of stock options relating to 8,000 shares of common stock. These options have an exercise price of $1.20 per share and expire on July 6, 2036. All 8,000 options vest and become exercisable on the one-year anniversary of the grant date, as long as he continues as a service provider through that date. After this grant, he holds a total of 23,573 stock options directly.
BioCardia, Inc. director Bill Facteau received a grant of stock options representing the right to buy 8,000 shares of common stock. The options have an exercise price of $1.20 per share and expire on July 6, 2036.
All 8,000 option shares vest and become exercisable on the one-year anniversary of the grant date, as long as he continues as a service provider through that date. After this grant, his directly held option awards total 23,729 underlying shares.